R Ignoffo
Impact in
- Hepatology top 2%
- Hepatocellular Carcinoma Treatment and Prognosis
- Otorhinolaryngology top 5%
- Head and Neck Cancer Studies
Papers in
- Oncology 5
- Pancreatic and Hepatic Oncology Research 2
- Cancer Treatment and Pharmacology 2
- Colorectal Cancer Treatments and Studies 2
-
- Angiogenesis and VEGF in Cancer 1
- Co-authors
- B.J. Lewis (2 shared papers)Michael Friedman (2 shared papers)Robert Stagg (2 shared papers)David C. Hohn (1 shared paper)Anthony A. Rayner (1 shared paper)John F. Hannigan (1 shared paper)Joel Z. Melnick (1 shared paper)D. Höhn (1 shared paper)
- Journals
- Journal of Clinical Oncology (2 papers)Cancer Practice (1 paper)PubMed (4 papers)
- Partner nations
- United States
In The Last Decade
R Ignoffo
7 papers receiving 611 citations
Peers
Comparison fields: 5 of 63
- Hepatology 329
- Otorhinolaryngology 58
- Oncology 273
- Pulmonary and Respiratory Medicine 192
- Surgery 161
Countries citing papers authored by R Ignoffo
This map shows the geographic impact of R Ignoffo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R Ignoffo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R Ignoffo more than expected).
Fields of papers citing papers by R Ignoffo
This network shows the impact of papers produced by R Ignoffo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R Ignoffo. The network helps show where R Ignoffo may publish in the future.
Co-authors
The 25 scholars most cited alongside R Ignoffo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 1989 | 349 | |
| 2 | Randomized clinical trial of chlorhexidine versus placebo for prevention of oral mucositis in patients receiving chemotherapy. | 1996 | 131 |
| 3 | 1985 | 122 | |
| 4 | Sequential infusions of methotrexate and 5-fluorouracil in advanced cancer: pharmacology, toxicity, and response. | 1985 | 17 |
| 5 | 1998 | 7 | |
| 6 | Adriamycin-cyclophosphamide treatment of squamous cell carcinoma of the cervix. | 1978 | 7 |
| 7 | Dolasetron. A new 5-hydroxytryptamine3 receptor antagonist. | 1997 | 1 |
About R Ignoffo
R Ignoffo is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Hepatology and Obstetrics and Gynecology, having authored 7 papers that have together received 634 indexed citations. Recurring topics across this work include Pancreatic and Hepatic Oncology Research (2 papers), Cancer Treatment and Pharmacology (2 papers), Colorectal Cancer Treatments and Studies (2 papers), Hepatocellular Carcinoma Treatment and Prognosis (2 papers), Ovarian cancer diagnosis and treatment (1 paper), Angiogenesis and VEGF in Cancer (1 paper), Liver Diseases and Immunity (1 paper) and Lung Cancer Treatments and Mutations (1 paper). The work is most often cited by research in Hepatology (329 citations), Otorhinolaryngology (58 citations), Oncology (273 citations), Pulmonary and Respiratory Medicine (192 citations) and Surgery (161 citations). R Ignoffo has collaborated with scholars based in United States. Frequent co-authors include B.J. Lewis, Michael Friedman, Robert Stagg, David C. Hohn, Anthony A. Rayner, John F. Hannigan, Joel Z. Melnick, D. Höhn, Douglas G. Altman and Christine Miaskowski. Their work appears in journals such as Journal of Clinical Oncology, Cancer Practice and PubMed.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.